Back to top
more

Actinium Pharmaceuticals (ATNM)

(Delayed Data from AMEX)

$6.87 USD

6.87
206,378

+0.31 (4.73%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $6.89 +0.02 (0.29%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Better trading starts here.

Brokerage Reports

Research for ATNM

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Actinium Pharmaceuticals, Inc. [ATNM]

Reports for Purchase

Showing records 1 - 20 ( 89 total )

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1

03/26/2024

Daily Note

Pages: 8

Iomab-ACT Looks to Improve CAR-T Therapy in New Clinical Collaboration With UT Southwestern

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 2

03/19/2024

Daily Note

Pages: 8

Appetite Remains High For Radiopharmaceuticals; We See Actinium As Ripe For Takeout

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 3

03/11/2024

Daily Note

Pages: 7

A Glowing Start With Strategic Growth Option For Actinium-225

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 4

02/26/2024

Company Report

Pages: 8

Iomab-B''s Ongoing Impact at TCT ''24

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 5

02/23/2024

Company Report

Pages: 10

TCT ''24 Presentations Underscore Iomab-B''s Differentiated Efficacy in TP53+ Settings and Beyond

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 6

12/11/2023

Company Report

Pages: 9

ASH Presentation Highlights Iomab-B''s Capacity to Improve Key Outcomes in High Risk TP53+ r/r AML Population

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 7

11/06/2023

Company Report

Pages: 7

Actimab-A Exhibits Robust CD33+ Targeting Activity and Disrupts Immunosuppression in Preclinical Experiments

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 8

11/03/2023

Company Report

Pages: 6

3Q23 Results; Iomab-B Strong in TP53+ Patients; BLA Filing on Track for 1H24

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 9

10/04/2023

Company Report

Pages: 6

A Favorite Under-the-Radar Indication of Ours Gets More NIH Cash; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 10

10/03/2023

Daily Note

Pages: 6

Pharma Interest in Radiopharma Remains Glowing; Iomab-B BLA Coming Soon

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 11

09/07/2023

Daily Note

Pages: 5

Extended Survival Data Reaffirms Actimab-A as Potential Backbone Combination Therapy for AML

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 12

08/15/2023

Company Report

Pages: 6

2Q23 Results; Execution Focus; Iomab-B BLA and EAP Launch On Track for 2H23; Price Target Adjusted to $50

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 13

05/16/2023

Company Report

Pages: 6

1Q23 Results; Radiotherapy Portfolio Shows No Signs of Slowing Down; Iomab-B BLA Submission Expected in 2H23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 14

04/20/2023

Company Report

Pages: 9

CD33- and HER3-Targeting Radiotherapeutics Reveal Preclinical Efficacy in Multiple Solid Tumor Models

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 15

04/03/2023

Company Report

Pages: 8

2022 Results; Key Regulatory Milestones Ahead; BLA Submission For Iomab-B Expected 2H23

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 16

02/28/2023

Company Report

Pages: 8

KOL Call Highlights Importance of Iomab-B For Addressing Advanced r/r AML and Beyond

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 17

02/21/2023

Company Report

Pages: 10

Thank You SIERRA; Active r/r AML Patients Could Have New Meaningful Option; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 18

02/07/2023

Company Report

Pages: 6

Broad CRADA With NCI Shines Bright Light on Actimab- A; Major Cost Savings Potential; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 19

12/12/2022

Company Report

Pages: 7

Actimab-A / CLAG-M Combination Data Don''t Disappoint at ASH; Full Positive SIERRA Data Likely Early 2023

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Company: Actinium Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 20

11/15/2022

Company Report

Pages: 7

3Q22 Results; Full Data Looks From SIERRA and Actimab-A/CLAG Coming Soon

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party